Boston Scientific stent sales reflect growing competition: Boston Scientific's drug-eluting coronary stent sales totaled $428 million in the first quarter, an 8.5% decline from the prior-year period and a 1.6% sequential decrease from the fourth quarter of 2007, the firm reported April 21. The drop was due in part to price cuts and increased competition in the U.S. with the launch in February of Medtronic's Endeavor zotarolimus-eluting stent. Wachovia analyst Larry Biegelsen estimates that Boston Scientific's Taxus paclitaxel-eluting stent ceded four points of U.S. market share to Endeavor during the quarter versus seven points for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent. Boston Scientific estimates that Endeavor held U.S. share of 12%-13% at the end of the quarter. Despite the market share shift, Chief Operating Officer Paul LaViolette pointed to "clear evidence of recovery" in the drug-eluting stent market. The firm's cardiac rhythm management sales of $565 million in Q1 reflect a 4.8% year-over-year advance
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The rate at which new documents to support the implementation of EU medtech regulations are issued has slowed of late; but June bucked the trend, with a flurry of activity.
The NHS 10-Year Plan officially released on July 3 will crystalize NICE’s Rules-Based Pathway – a new concept for medtech evaluation that will come with a guarantee of funding – but only for a select number of products. Government to also introduce “innovator passport” to speed innovation into NHS.
The FDA has released draft guidance clarifying UDI rules for drug- and device-led combination products. The document specifies labeling requirements and makes recommendations to reduce confusion between UDIs and NDCs. Comments are being accepted until Sept. 24.
